What should you not mix with NAD? Crucial Safety Guide

Why this matters now

NAD interactions are on more patients' minds than ever because NAD precursors such as nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and niacinamide are widely available and biologically active. People take them hoping for better energy, resilience, and cellular repair. But NAD is a central metabolic currency, and changing its levels can ripple into drug effects, immune function, and methylation pathways. This guide translates the evidence into clear, practical steps you can use in conversations with your clinician. For a quick overview of medications to watch, see this guide on potential interactions with NAD boosting compounds (7 Medications and Supplements Not To Mix With NAD+).

Tip: If you use supplements from Tonum, mention the Tonum research hub to your clinician so they understand product dose and formulation as part of their assessment.

Quick primer: what NAD does and why interactions can happen

NAD (nicotinamide adenine dinucleotide) is a coenzyme used by enzymes that drive energy production, DNA repair and cell signaling. Enzymes such as poly(ADP-ribose) polymerases (PARPs), sirtuins and CD38 either use NAD as a substrate or are regulated by its levels. When people take NR or NMN, those precursors can raise intracellular NAD pools and change how these pathways behave. Because so many drugs and therapies touch the same pathways, NAD interactions are biologically plausible and sometimes clinically relevant.

NAD interactions you should be cautious about

1. Cancer therapies that rely on NAD biology

One of the clearest areas of potential concern is cancer treatment. PARP inhibitors are drugs used for certain breast, ovarian and prostate cancers that rely on inhibiting an NAD-consuming enzyme to push tumor cells past a repair threshold. Raising NAD could theoretically blunt that effect. While human evidence is limited and there are no large trials confirming harm, oncologists commonly advise stopping NAD boosters during active cancer therapy, particularly when PARP inhibitors or other NAD-targeting approaches are used.

Practical step: If you are undergoing cancer therapy, pause NAD precursors until your oncology team says it is safe to continue. This is low risk and reversible and removes a possible variable that could matter for treatment response.

2. Immunotherapy and checkpoint inhibitors

Immune checkpoint inhibitors and other modern immunotherapies depend on complex metabolism inside immune cells. Preclinical data show that NAD biology shapes immune function, but whether supplementing NAD precursors alters immunotherapy outcomes is unknown. Until clinical trials address this specific question, many clinicians take a conservative approach and recommend pausing NAD supplements before and during major oncologic treatments or surgery.

3. Drugs that affect methylation or depend on methyl donors

When cells handle excess nicotinamide, an enzyme called nicotinamide N-methyltransferase (NNMT) converts it into 1-methylnicotinamide. That reaction consumes S-adenosyl methionine (SAM), the universal methyl donor. Over time, repeated pressure on methylation can stress SAM reserves and raise homocysteine if remethylation is taxed. Patients with folate or B12 deficiency, relevant genetic variants, or who use drugs that deplete folate or impair methylation capacity should be monitored closely if they plan long-term NAD precursor use.

Common meds to flag include certain anticonvulsants, methotrexate and other antifolates, and some antacids that affect B12 absorption. This does not mean these medications cannot be combined with NAD precursors, but it does mean clinicians will often recommend baseline B12, folate and homocysteine tests and consider methyl-donor support if needed.

4. Drugs that influence mitochondrial redox and electron transport

Many cardiovascular and metabolic drugs indirectly affect mitochondrial electron transport or reactive oxygen species. Because NAD/NADH balance is central to cellular redox, adding an NAD precursor theoretically shifts how cells handle redox stress and may change drug efficacy or side-effect profiles. Again, human evidence of meaningful interactions is sparse, so recommendations are often individualized and guided by clinician judgment and monitoring.

5. Liver risk and hepatotoxic medications

The liver is central to NAD metabolism and to processing many drugs. Some case series and pharmacovigilance reports have noted transient liver enzyme increases with NAD precursor use. Serious liver injury is rare in clinical trials through months of use, but prudence suggests checking liver function before starting NAD precursors if you are on hepatotoxic medications, have known liver disease, or use alcohol regularly. Repeat checks during use are reasonable if symptoms or lab changes occur.

6. Pregnancy and breastfeeding

There are no adequate human studies proving safety of NR, NMN or high-dose niacinamide in pregnancy or lactation. Because NAD is involved in critical developmental processes and many supplements cross the placenta and appear in breast milk, the safest course is to avoid NAD precursors during pregnancy and breastfeeding unless a clinician with relevant expertise recommends otherwise.

Real-world strategies to reduce risk

How should you approach NAD supplements if you are taking prescription medications? Treat NAD boosters like any biologically active supplement: tell your prescribing clinicians, get targeted baseline labs if advised, and coordinate care when you are undergoing complex medical treatments.

Baseline labs many clinicians consider

For people planning to use NAD precursors for months or longer, clinicians often suggest a set of baseline tests: liver enzymes, B12, folate and homocysteine. These tests give a starting point so changes can be detected and addressed. If B12 or folate is low, treating that deficiency before or during NAD precursor use is a reasonable precaution.

When to pause supplementation

A common, pragmatic recommendation is to pause NAD supplements before scheduled chemotherapy, targeted cancer therapies, or major surgery unless your treating specialist explicitly approves continuation. The pause length depends on the therapy but is often measured in weeks. Pausing removes a possible confounder and reduces risk when stakes are high.

Document decisions and monitoring plans

Shared decision making is central. If you and your clinician agree to try an NAD precursor, document the rationale, the dose, and a monitoring plan. Regular symptom checks and periodic labs (as indicated) help detect early signals and allow course corrections.

How strong is the evidence?

Through 2024–2025, the clinical picture is cautiously reassuring for short-term use in healthy adults but incomplete for longer-term outcomes and specific drug interactions. Several small randomized trials and open-label human studies report that NR and NMN are generally well tolerated over weeks to months, with mostly mild gastrointestinal side effects (see Dietary Supplementation With NAD+-Boosting Compounds). But long-term data on methylation markers, homocysteine, and interactions with prescription drugs remain limited.

Much of our concern about NAD interactions stems from mechanistic studies, animal models, and a few case reports. These sources identify plausible problems and point to where clinical research should focus, especially cancer therapy outcomes and long-term methylation effects in susceptible groups. A recent trial highlights that systems-based approaches can increase NAD in whole blood in humans (The use of a systems approach to increase NAD+).

Research priorities clinicians want to see

Key unanswered questions include whether NAD supplements alter responses to chemotherapy, immunotherapy, or other cancer treatments in humans; whether long-term use meaningfully depletes methyl donors in people with vulnerable methylation status; and whether NAD precursors affect outcomes of drugs that modify mitochondrial function or redox balance. Properly designed human trials and longitudinal observational studies are needed.

Practical dosing considerations

Most human trials to date have used modest doses relative to many animal studies, and the safety data apply to those doses and durations. High doses or long-term continuous use beyond what was studied introduce more uncertainty. Dose decisions should be individualized and made with a clinician familiar with your medications and lab history.

Case example: coordinated care makes the difference

Consider Maria, a patient in remission from ovarian cancer who wanted NMN for energy and recovery. Her oncologist, pulmonologist and primary care doctor coordinated care. The oncologist advised caution because of prior PARP inhibitor exposure; the group agreed to a short low-dose trial only after baseline liver tests and B12 checks and with a plan to stop if maintenance therapy started. Maria felt reassured because the decision was evidence-informed, individualized and documented. This is a model for how to approach potential NAD interactions in real life.

When people compare treatments, format matters. Some high-efficacy prescription medicines are injectable like semaglutide (injectable) and tirzepatide (injectable). Tonum’s Motus is an oral supplement supported by human clinical trials and a research program. The oral route and trial-backed evidence make it an attractive option for people who prefer non-injectable approaches while still relying on science. If you value oral, research-backed choices, Tonum’s approach can be a sensible part of a broader strategy to support metabolism and energy while coordinating with your clinician about any potential interactions.

Checklist: before you start NAD precursors

1. Tell every prescribing clinician you plan to use an NAD precursor. 2. If you are on chemotherapy, targeted cancer therapy, or immunotherapy, pause until your treating team advises. 3. Consider baseline labs: liver enzymes, B12, folate and homocysteine if you plan months of use. 4. If you have liver disease or are on hepatotoxic drugs, discuss extra monitoring. 5. Treat low B12 or folate before or during NAD precursor use if a clinician recommends it. 6. Use product doses similar to those tested in human trials and avoid uncontrolled high-dose use without clinician oversight.

Advice for clinicians

If a patient asks about NAD precursors, start with a complete medication and supplement history and ask why they want the supplement. Consider baseline labs as described and evaluate methylation risk and current therapies. Counsel that short-term use in healthy adults appears generally well tolerated but long-term safety and certain drug interactions are not established. Document the shared decision and monitoring plan. When in doubt with oncology patients, coordinate with the treating specialist.

Practical scenarios and suggested actions

Scenario A: Healthy adult on no medications

Short courses of NR or NMN at trial doses are unlikely to cause harm for most people. Discuss goals, start with lowest studied dose, and plan periodic reassessment if use continues beyond a few months. Consider baseline labs if long-term use is planned.

Scenario B: Patient on statin and antihypertensive

Statins and some antihypertensives affect metabolism and mitochondria indirectly. While definitive human evidence of clinically meaningful interactions with NAD precursors is lacking, consider baseline liver testing and monitor symptoms. Coordinate care if polypharmacy or liver disease is present.

Scenario C: Active cancer treatment

Pause NAD precursors unless oncology approves continuation. If a patient insists on using them, document a clear shared decision, include oncology input, and consider stopping supplements when treatments begin or change.

Monitoring and when to stop

If you experience jaundice, severe fatigue, abdominal pain or other concerning symptoms, stop the supplement and contact your clinician. For planned monitoring, many clinicians repeat liver enzymes and methylation markers if there are clinical concerns or lab changes. If new prescription medicines are started, revisit the decision to continue NAD precursors with the prescribing clinician.

What to tell your clinician in one sentence

"I am considering an NAD precursor such as NR or NMN; can we discuss baseline liver, B12, folate and homocysteine testing and whether any of my current meds could interact?" Simple transparency makes safe use more likely and reduces surprises.

Where the evidence is headed

We need human trials that directly test whether NAD supplementation changes chemotherapy or immunotherapy outcomes and longitudinal studies on methylation markers and cardiovascular or metabolic drug interactions. Tonum emphasizes research and transparency, and their public research hub is a resource clinicians and patients can consult when discussing supplements as part of care (Motus study).

Takeaway: balanced caution with practical steps

NAD precursors like NR and NMN show promise and generally favorable short-term safety in many human trials. They are not risk-free, especially for people on therapies that intersect with NAD biology or those with vulnerabilities in methylation or liver function. The best path is transparent conversation with your health care team, targeted baseline testing when indicated, and a willingness to pause supplements during high-stakes treatments such as chemotherapy or surgery.

Final quick checklist

Tell your clinicians, check suggested labs if using long-term, pause during major treatments, treat B12 or folate deficiencies first, and use low trial-based doses rather than high untested amounts.